Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Chiaretto Calo
Nov 14, 2023 6:32AM ET
According to analysts, PSTV stock is rated as a "Strong Buy." The average 12-month stock price forecast is $10.00, representing a substantial increase of over 525% from the current price.
Innovative Drug Development: Plus Therapeutics focuses on developing treatments for cancer and other diseases. Their lead drug candidate, Rhenium-186Re obisbemeda, targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. They are also working on other promising treatments for solid organ cancers.
FDA Orphan Drug Designation: The company recently received U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the treatment of breast cancer with leptomeningeal metastases. This designation can provide certain benefits, including market exclusivity upon approval, assistance in clinical study design, tax credits, and exemption from FDA user fees.
Share Repurchase Program: Plus Therapeutics announced a share repurchase program, indicating confidence in their financial stability and future prospects.
Clinical Trial Progress: The company has been making progress in its clinical trials. For instance, they completed dosing in Cohort 4 of the ReSPECT-LM Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases and plan to move into the next cohort following safety reviews.
0
0
